ATE293169T1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents

Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Info

Publication number
ATE293169T1
ATE293169T1 AT02729440T AT02729440T ATE293169T1 AT E293169 T1 ATE293169 T1 AT E293169T1 AT 02729440 T AT02729440 T AT 02729440T AT 02729440 T AT02729440 T AT 02729440T AT E293169 T1 ATE293169 T1 AT E293169T1
Authority
AT
Austria
Prior art keywords
latency
pharmaceutically active
fusion protein
nucleic acid
construct
Prior art date
Application number
AT02729440T
Other languages
English (en)
Inventor
Yuti Chernajovsky
Hanna Stina Dreja
Gillian Adams
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of ATE293169T1 publication Critical patent/ATE293169T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02729440T 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen ATE293169T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (1)

Publication Number Publication Date
ATE293169T1 true ATE293169T1 (de) 2005-04-15

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729440T ATE293169T1 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Country Status (10)

Country Link
US (1) US6942853B2 (de)
EP (1) EP1349944B1 (de)
JP (1) JP4201253B2 (de)
AT (1) ATE293169T1 (de)
AU (1) AU2002219345B2 (de)
DE (1) DE60203692T2 (de)
DK (1) DK1349944T3 (de)
ES (1) ES2240740T3 (de)
GB (1) GB0100551D0 (de)
WO (1) WO2002055098A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
EP1572908A4 (de) * 2002-02-14 2008-10-22 William J Rutter Chimäre moleküle zur spaltung in einem behandelten wirt
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
AU2007351813B2 (en) * 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
EP2413958A4 (de) 2009-03-31 2014-04-02 Univ East Carolina Cytokine und neuroantigene zur behandlung von immunerkrankungen
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
EP2878308B1 (de) * 2013-12-02 2018-10-31 Thomas Harder Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
EP3856764A4 (de) 2018-09-27 2022-11-02 Xilio Development, Inc. Maskierte cytokin-polypeptide
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス, インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント, インコーポレイテッド 腫瘍特異的に切断可能なリンカー
AU2022237504A1 (en) 2021-03-16 2023-10-05 Cytomx Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
EP1770161A3 (de) 1993-05-12 2008-04-23 Genetics Institute, LLC BMP-11 Zusammenstellungen
CA2712304C (en) 1994-06-10 2011-10-25 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
CA2288943C (en) * 1997-04-30 2011-02-01 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
EP1117805A2 (de) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modifizierte proteine der tgf-beta superfamilie
JP2004508838A (ja) * 2000-09-11 2004-03-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 組合せ蛍光エネルギー移動タグ及びそれらの使用

Also Published As

Publication number Publication date
GB0100551D0 (en) 2001-02-21
DK1349944T3 (da) 2005-07-25
WO2002055098A2 (en) 2002-07-18
JP2004520031A (ja) 2004-07-08
US6942853B2 (en) 2005-09-13
DE60203692T2 (de) 2006-03-02
DE60203692D1 (de) 2005-05-19
AU2002219345B2 (en) 2006-03-16
JP4201253B2 (ja) 2008-12-24
WO2002055098A3 (en) 2002-11-21
EP1349944B1 (de) 2005-04-13
US20020151478A1 (en) 2002-10-17
ES2240740T3 (es) 2005-10-16
EP1349944A2 (de) 2003-10-08

Similar Documents

Publication Publication Date Title
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE500323T1 (de) Subtilisin-variante
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
WO2002014358A3 (en) Novel secreted proteins and their uses
BR9814276A (pt) Antìgenos de superfìcie
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
AU2003222717A8 (en) Streptavidin-binding peptide
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
WO2004054607A3 (de) Stabile therapeutische proteine
DE69941433D1 (de) Von protease typ ii spaltbares peptid
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
Godat et al. Inhibition of a cathepsin L-like cysteine protease by a chimeric propeptide-derived inhibitor
WO2004053117A3 (en) Serine protease
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
ATE278011T1 (de) Human dnase ii
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
TH62241A (th) ไบคูนินของคน
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties